Skip to content

Neuropace, Inc. NPCE Enterprise value

Enterprise value at other companies

Medtronic logo
MedtronicMDT
$131.22B-3.2%
LivaNova logo
LivaNovaLIVN
$3.28B+58.0%
ClearPoint Neuro logo
ClearPoint NeuroCLPT
$297.01M-7.1%
Inspire Medical Systems logo
Inspire Medical SystemsINSP
$1.42B-70.0%
ARS Pharmaceuticals, Inc. logo
ARS Pharmaceuticals, Inc.SPRY
$869.56M-27.2%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$2.27B-4.1%

Other financials

Income statement

See full
Revenue$22.1M-2.0%
Gross profit$18.0M+4.1%
Operating income-$5.6M-8.2%
Net income-$6.7M-1.5%
EPS (diluted)-$0.20+4.8%

Balance sheet

See full
Cash & equivalents$15.6M-42.4%
Total debt$70.5M-3.7%
Total equity$14.5M-40.4%
Total assets$98.9M-10.3%

Cash flow

See full
Operating cash flow-$5.9M+21.1%
CapEx$117.0K+216%
Free cash flow-$6.0M+20.0%

Valuation

See full
Market cap$557.77M+63.4%
P/S5.6×+1.6×

Profitability

See full
Gross margin78.3%+3.5pp
Operating margin-16.8%-3.5pp
Net margin-21.7%-4.5pp
FCF margin-10.3%-3.5pp

Returns & leverage

See full
Return on equity-111.4%-13.1pp
Debt / equity4.9×+1.9×
Current ratio5.4×-1.2×

Where this comes from

Calculated from Neuropace, Inc.’s reported figures.

The official record: Neuropace, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neuropace, Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neuropace, Inc.'s enterprise value?
Neuropace, Inc. (NPCE) reported enterprise value of $497.55M in Q1 2026.
How has Neuropace, Inc.'s enterprise value changed year-over-year?
Neuropace, Inc.'s enterprise value increased by 11.5% year-over-year, from $446.17M to $497.55M.
What is the long-term trend for Neuropace, Inc.'s enterprise value?
Over 4 years (2021 to 2025), Neuropace, Inc.'s enterprise value has grown at a 18.8% compound annual growth rate (CAGR), from $283.06M to $563.29M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.